CEPI to provide up to $328m for development of Clover’s Covid-19 vaccine candidate

This article was originally published here

Clover will use the funding to conduct the global pivotal phase 2/3 efficacy clinical trial of the protein-based S-Trimer Covid-19 vaccine candidate. It will also use the funds

The post CEPI to provide up to $328m for development of Clover’s Covid-19 vaccine candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply